Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0038358 (
gastric ulcer
)
5,179
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Wei-Yan-Ning and
Furazolidone
were used separately in the treatment of 62 cases of gastritis and
gastric ulcer
caused by pyloric campylobacteria. The examinations one month later proved, through the gastrofiberscopy and pathological test as well as the urease test, that, among the 40 cases of Wei-Yan-Ning group, there were 25 cures (62.5%), prominent effect for 9 cases (22.5%), improvement for 3 cases (7.5%). The total effective rate was 92.5%. Among the 22 cases of the
Furazolidone
group, there were 7 cures (31.8%), prominent effect for 5 cases (22.7%), improvement for 4 cases (18.2%). The total effective rate was 72.7%. As for the improvement of symptom, the average time for the Wei-Yan-Ning group was 12.5 +/- 8.12 days; and the
Furazolidone
group was 21.63 +/- 7.87 days. Therefore, the effect of Wei-Yan-Ning group was superior to that of the
Furazolidone
group (P less than 0.05).
...
PMID:[Comparative study of the effect of wei-yan-ning and furazolidone in the treatment of gastritis and gastric ulcer caused by pyloric Campylobacter]. 260 37
Campylobacter pylori infection has been associated with duodenal ulcer,
gastric ulcer
, and non-ulcer dyspepsia. Although in vitro studies have shown that C. pylori is susceptible to most commonly used antibiotics, predictions from in vitro sensitivity studies have not led to a safe and generally effective therapy; C. pylori has proved to be very difficult to eradicate in vivo. We used the urea breath test to assess the susceptibility of C. pylori in vivo to various drugs. C. pylori was susceptible to bismuth subsalicylate, bismuth subnitrate, and furazolidone. C. pylori was not susceptible (i.e., urease activity remained despite administration of the drug) to the following drugs: 1) antiulcer agents (cimetidine, ranitidine, famotidine, omeprazole, misoprostol, sucralfate, liquid antacids); 2) NSAIDs (aspirin, indomethacin, ibuprofen, naproxen, tolmetin); 3) antibiotics (oral penicillin V, trimethoprim-sulfamethoxazole, dicloxacillin); 4) salts (lithium, ferrous sulfate, gold); 5) miscellaneous (acetaminophen, phenytoin, hydrochlorothiazide, propranolol, metoprolol, metoclopramide, ursodeoxycholic acid). Oral antimicrobials can be administered directly onto the site of infection, so that a very low oral dose will provide many multiples of the in vitro minimal inhibitory concentration.
Furazolidone
suspension (7 mg) was administered seven times daily (daily dose 49 mg) to three individuals infected by C. pylori during suppression of gastric acid secretion with famotidine (40 mg bid). After 4 days, all subjects had significant reductions in urease activity (two to normal and one to a borderline value). This response suggested that very low-dose therapy may be useful either alone or combined with bismuth. Conclusive establishment of an etiologic (or major contributory) relationship of C. pylori to ulcer disease will require a safe and reliable method to eradicate the organism from the stomach and duodenum.
...
PMID:In vivo susceptibility of Campylobacter pylori. 291 80